RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Doravirine 100 mg Dose Selected for Subsequent Studies Based on Exposure—Response Analysis
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 28
SP 21
OP 22
DO 10.1177/155989771428013
UL http://mdc.sagepub.com/content/14/28/21.abstract
AB Part 1 of A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus-1 Infected Participants (MK-1439-007) [NCT01632345] examined the safety, tolerability, pharmacokinetics, and efficacy of 4 doses of doravirine (25, 50, 100, and 200 mg once daily) versus efavirenz, both taken with emtricitabine-tenofovir. The Part 1 efficacy and safety results demonstrated that all 4 doses of doravirine had potent antiretroviral activity and fewer drug-related adverse events than efavirenz [Morales-Ramirez et al. CROI 2014].